XOMA’s (XOMA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of XOMA (NASDAQ:XOMA) in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $123.00 price objective on the biotechnology company’s stock.

Separately, StockNews.com downgraded XOMA from a “hold” rating to a “sell” rating in a research report on Friday, December 27th.

XOMA Stock Up 0.3 %

Shares of XOMA stock opened at $25.74 on Tuesday. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. The company has a market cap of $303.29 million, a P/E ratio of -7.40 and a beta of 0.92. The firm’s 50 day moving average price is $29.20 and its 200-day moving average price is $27.94. XOMA has a 52-week low of $18.57 and a 52-week high of $35.00.

Insider Buying and Selling

In other XOMA news, CEO Owen Hughes sold 21,881 shares of XOMA stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total transaction of $655,335.95. Following the completion of the sale, the chief executive officer now owns 34,979 shares of the company’s stock, valued at approximately $1,047,621.05. The trade was a 38.48 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 7.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets boosted its position in XOMA by 95.0% in the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 795 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of XOMA by 0.6% in the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after acquiring an additional 1,138 shares during the last quarter. Rhumbline Advisers increased its stake in shares of XOMA by 16.0% in the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after acquiring an additional 1,334 shares during the period. State Street Corp raised its holdings in shares of XOMA by 1.2% during the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after purchasing an additional 1,754 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in XOMA by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares during the period. 95.92% of the stock is currently owned by hedge funds and other institutional investors.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.